Stahel sees Scale in India

Ex-Shire CEO Stahel brings business acumen to Indian diabetes play Connexios

Indian biotech Connexios Life Sciences Pvt. Ltd. is hoping to pattern itself after Western R&D-focused biotechs by building a pipeline of compounds against novel targets backed by a strong understanding of disease biology. The scale of the company's research team has attracted Rolf Stahel as non-executive chairman to add international business development and marketing acumen to the science that is already in development.

Like other small biotechs, Connexios hopes to fill the gap at pharma companies such as AstraZeneca plc that have become more dependent upon in-licensing to

Read the full 877 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE